Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 151

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 151
---
ological malignancies with approved CAR-T cell therapies, cure rates do not
exceed 60%. Nevertheless, despite such limitations, sales of CAR-T cell therapies are anticipated to grow rapidly over the next several years
and are expected to exceed $10 billion globally by 2030.

We believe that the preferential
attributes engineered into our CER-T cell therapy enables us to overcome many of the limitations which hinder the wider application of
CAR-T technology. Our CER-T cells employ a novel targeting mechanism that targets a ligand broadly expressed on tumor cells but not healthy
cells. Specifically, CER-1236 targets the TIM-4 Ligand (TIM-4-L), otherwise known as phosphatidylserine (“PS”), a critical
component of the cell’s plasma membrane that has a key role in cell cycle regulation. Exposure of TIM-4-L on the outer surface
of the plasma membrane acts as an “eat-me” signal and marks abnormal, stressed and dying or dead cells for phagocytosis.
The pro-phagocytic activities of CER-T cells are designed to integrate innate immune effector functions into cytotoxic killer T cells,
creating within a single T cell the ability to directly mediate cytotoxic effects and indirectly prime other immune cells. Moreover,
in preclinical studies, we have observed that CER-1236 cells exhibit superior cross-presentation abilities compared to conventional T
cells, potentially triggering a broad complement of immune effector cells against tumors. Since externally oriented TIM-4-L is ubiquitously
expressed by numerous cancer cell types but has very limited exposure on normal healthy cells, we envision CER-1236 as having differentiated
therapeutic utility with application across a wide array of cancer types.

We have patterned the design
of our CER-T constructs based upon many of the components found in existing conventional CAR-T cell therapies, which we believe could
shorten development timelines and enhance commercial application. The processes and protocols used to genetically modify a patient’s
T cells to produce CAR-T cells are already well recognized, as is the use of lentivirus in the manufacture of these therapies. Accordingly,
we have developed CER-T cell manufacturing processes that closely resemble those used to produce existing engineered CAR-T cells. We
also expect to benefit from the well-defined and recognized regulatory guidelines established by both U.S. and European regulatory
authorities related to CAR-T therapies and their use. In contrast to these attributes, we believe that other emerging CAR-based drug
candidates which